The overall objective for Core D is to give the team of investigators associated with this multi-institutional Program Project a chance to form a synergistic team by facilitating the interaction among Project and Core Leaders, Research Administration at the Dana-Farber Cancer Institute and at the collaborating institutions, and NIH representatives. The network of collaborating scientists includes researchers in different parts of the U.S. and extends to Europe (Dr. Dietrich, Frankfurt, Germany) and Africa (Dr. Siuluta, Lusaka, Zambia).
The Specific Aims of Core D are: 1. To provide administrative support in order to facilitate the collaboration among Project and Core Leaders. 2. To facilitate the exchange of information and reagents among Project and Core Leaders and the various collaborating scientists. 3. To provide statistical support to all Program Project scientists. 4. To organize the yearly site visit and External Scientific Advisory Board (SAB) meeting, the monthly telephone conferences, and individual visits of Drs. Wood, Else, Hu or their colleagues to Boston. 5. To set scientific priorities, monitor overall progress, and evaluate the timely achievement of scientific mile stones. This will be achieved by the Internal Steering Committee (ISC) with input from the SAB and the NIAID Program Officer. The ISC committee is comprised of all Project and Core Leaders. 6. To assure the timely achievement of the experimental goals within the budget limits. 7. To facilitate timely completion of reports, public dissemination of new data at meetings, and publication of manuscripts. To achieve these objectives, the Principal Investigator depends on the support of trained professionals with excellent organizational skills, a Program Development Associate and a Financial Coordinator with MBA training.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048240-10
Application #
8327073
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2011-09-05
Project End
2013-08-16
Budget Start
2011-09-05
Budget End
2013-07-31
Support Year
10
Fiscal Year
2011
Total Cost
$159,782
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Watkins, Jennifer D; Sholukh, Anton M; Mukhtar, Muhammad M et al. (2013) Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27:F13-20

Showing the most recent 10 out of 77 publications